Safety, Efficacy, Tolerability and Pharmacokinetics of LF111 (Drospirenone 4.0 mg) During 13 Cycles

NCT ID: NCT02269241

Last Updated: 2019-08-06

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE3
• Total Enrollment: 1552 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2014-10-09
• Study Completion Date: 2017-10-04

Brief Summary

To demonstrate the contraceptive efficacy of LF111 . To demonstrate the safety and tolerability of LF111 and assessment of pharmacokinetics of LF111.

Detailed Description

This trial is a prospective, multicenter, open-label, non-controlled trial in female subjects, including adolescents between the ages of 15+(inclusive) who present to the clinic seeking contraception, who are postmenarcheal and premenopausal.

At screening, informed consent will be obtained and the screening procedures will be performed. After confirmation of the subject's eligibility, the subject will be provided with the investigational product and trained in the use of an electronic diary. Afterwards, the subjects will attend visit the clinical site on Day 20±2 of the 1st, 3rd, 6th and 9th cycles and on Day 29+2 of the 13th cycle. The last clinical site visit will occur 10-14 days after the 13th cycle visit.

The trial will include women who have never used hormonal contraceptives before consent (naïve users), women who have not used hormonal contraceptives in the past three months before consent or who have used hormonal contraceptives in the past but have a contraceptive-free time of less than three months before consent (previous users) as well as women directly switching from another hormonal method (switchers). Women who have used hormonal contraceptives in the past but have a contraceptive-free time of less than three months before consent are allowed to be included into the trial if they had at least one complete menstrual cycle before enrollment.

A population pharmacokinetic (PK) analysis planned in the whole subject population, will obtain sparse blood samples to determine plasma concentrations. In total, four blood samples will be collected: two samples each will be collected during the 1st cycle and during the 6th cycle of treatment.

Adverse events and safety information will be collected throughout the study.

Conditions

Contraception

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

LF111 (drospirenone)

single treatment arm receives LF111

Group Type: EXPERIMENTAL

LF111 (drospirenone)

Intervention Type: DRUG

One LF111 tablet once per day for 24 days followed by 4 placebo tablets for 4 days equals one cycle.

Interventions

LF111 (drospirenone)

One LF111 tablet once per day for 24 days followed by 4 placebo tablets for 4 days equals one cycle.

Intervention Type: DRUG

Other Intervention Names

CF111

Eligibility Criteria

Inclusion Criteria

1. Sexually active, postmenarcheal and premenopausal female subjects at risk of pregnancy including breastfeeding women with no upper age limit.

2. Female subjects at risk of pregnancy, between the ages of 15 and 17 (inclusive) provided that

• Applicable national, state and local laws allow subjects in this age group to consent/assent to receive contraceptive services, and
• All applicable laws and regulations regarding the informed consent/assent of the subjects to participate in clinical trials are observed.

3. Regular cycles during the last six months before consent/assent when not using hormonal contraception.

4. At least three complete menstrual cycles after delivery (only applicable for women who were pregnant within the last six months and for non-breastfeeding women). Breastfeeding women can be included six weeks after delivery irrespective of menstrual cycles post-delivery.

5. At screening, maximum systolic blood pressure (median value of three values) ≤ 159 mm Hg and diastolic blood pressure (median value of three values) ≤ 99 mm Hg.

6. Be able and willing to provide written informed consent or assent if the subject is adolescent, prior to undergoing any trial-related procedure.

7. Willing to use trial contraception for thirteen 28-day cycles.

8. Be willing to have intercourse each cycle of trial without the need to use back-up contraceptive.

9. Be willing to state that, to her best knowledge, her male sexual partner(s):

• Has not had a vasectomy or been previously diagnosed as infertile.
• Has not been previously diagnosed or suspected of human immunodeficiency virus (HIV) unless he has subsequently had a negative HIV test.
• Has not been known to have engaged in homosexual intercourse in the past five years unless he has had negative HIV test results since then.
• Has not shared injection drug needles in the past unless he has had a negative HIV test at least six weeks since last use.

10. Agree not to participate in any other clinical trials during the course of this trial.

Exclusion Criteria

1. Pregnant.

2. Subject is known to or suspected of not being able to comply with the trial protocol, the use of the trial medication or the use of the trial diary.

3. History of infertility.

4. Abnormal finding on pelvic, breast or ultrasound examination that in the investigator's opinion contraindicates participation in the trial.

5. Unexplained amenorrhea.

6. Known polycystic ovary syndrome.

7. Women ≥21 years of age with a Papanicolaou (pap) smear reading LGSIL or higher at screening (or six months prior to screening date). Human papilloma virus (HPV) testing in subjects with atypical squamous cells of undetermined significance (ASC-US) can be used as an adjunctive test.

• Subjects with ASC-US can be included if they are negative for high-risk HPV strains.
• Subjects <21 years of age do not require a pap smear.

8. Known contraindication or hypersensitivity to ingredients or excipients of the IMP (Investigational Medicinal Product), including:

1. Renal insufficiency

2. Hepatic dysfunction

3. Adrenal insufficiency

4. Current or history of venous thrombophlebitis or thromboembolic disorders (venous thromboembolism, which includes deep vein thrombosis and pulmonary embolism)

5. Current or history of cerebral-vascular or coronary-artery disease

6. Valvular heart disease with thrombogenic complications

7. Diabetes with vascular involvement

8. Headaches with focal neurological symptoms

9. Major surgery with prolonged immobilization

10. Known or suspected carcinoma of the breast

11. Known or suspected sex-steroid sensitive malignancies

12. Undiagnosed abnormal genital bleeding

13. Cholestatic jaundice of pregnancy or jaundice with prior hormonal contraceptive use

14. Liver tumor (benign or malignant) or active clinically significant liver disease.

9. Uncontrolled thyroid disorder (i.e., on stable dose of thyroid replacement for less than two months).

10. Uncontrolled concomitant diseases (i.e., not on a stable treatment dose for at least two months).

11. Evidence or history of alcohol, medication or drug abuse (within the last 12 months prior to consent/assent).

12. Known inherited or acquired predisposition to venous thromboembolism or arterial thromboembolism (e.g., factor V Leiden, Prothrombin mutation, Antiphospholipid antibodies) or bruising within the last 12 months prior to consent/assent.

13. Known or suspected HIV and/or hepatitis infection at screening.

14. Received a dose of depot medroxyprogesterone acetate (DMPA or Depo-Provera®) during the 10 months prior to consent/assent, or received any combined injectable contraceptive (e.g., Cyclofem®) during the six months prior to consent/assent, or no spontaneous menses since last injection.

15. Long-term treatment (longer than seven consecutive days within a month prior to V1b) of any medication that might interfere with the efficacy of hormonal contraceptives.

Prohibited medication include:

1. Anticonvulsants (e.g. phenytoin, carbamazepine, oxcarbazepine, topiramate, felbamate, primidone)

2. Barbiturates

3. Rifampin

4. Bosentan

5. Griseofulvin

6. St. John's wort (hypericum perforatum)

16. Administration of human chorionic gonadotropin (hCG) or intake of co-medication containing hCG within a month prior to V1b).

17. Progestin-releasing intra-uterine device (IUD) or contraceptive implant received or in place within the last two months prior to consent/assent.

18. Planned regular concomitant use of barrier contraceptive methods, spermicides, IUDs or other contraceptive measures (excepting occasional use for safety reasons, e.g., to reduce risk of infection).

19. Evidence or history of clinically significant psychiatric illness or suicide risk.

20. Participation in another trial of an investigational drug or device parallel to the current trial or less than 90 days before consent/assent, or previous participation in the current trial and dispensed trial medication.

21. Subject is a member of the investigator's or Sponsor's staff or a relative or family member thereof.

22. Any condition that, in the opinion of the investigator, may jeopardize protocol compliance or the scientific integrity of the trial.

• Minimum Eligible Age: 15 Years
• Eligible Sex: FEMALE
• Accepts Healthy Volunteers: Yes

Sponsors

Chemo France

INDUSTRY

Sponsor Role: collaborator

Laboratories Leon Farma, S.A.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Enrico Colli, MD

Role: STUDY_DIRECTOR

Exeltis

Locations

Alabama Clinical Therapeutics

Birmingham, Alabama, United States

Anaheim Clinical Trials, LLC

Anaheim, California, United States

WCCT Global

Costa Mesa, California, United States

Women's Health Care Research Corp.

San Diego, California, United States

Downtown Women's Health Care

Denver, Colorado, United States

Horizons Clinical Research Center, LLC

Denver, Colorado, United States

Stamford Therapeutics Consortium

Stamford, Connecticut, United States

Altus Research

Lake Worth, Florida, United States

Miami Research Associates

Miami, Florida, United States

Segal Institute for Clinical Research

North Miami, Florida, United States

Meridien Research - St. Petersburg

St. Petersburg, Florida, United States

Meridien Research - Tampa

Tampa, Florida, United States

Comprehensive Clinical Trials, LLC

West Palm Beach, Florida, United States

Fellows Research Alliance, Inc.

Savannah, Georgia, United States

Rosemark WomenCare Specialists

Idaho Falls, Idaho, United States

Bluegrass Clinical Research, Inc

Louisville, Kentucky, United States

Johns Hopkins School of Medicine

Baltimore, Maryland, United States

Beyer Research

Kalamazoo, Michigan, United States

Lawrence OBGYN Clinical Research, LLC

Lawrenceville, New Jersey, United States

The Center for Women's Health & Wellness, LLC

Plainsboro, New Jersey, United States

Southwest Clinical Research

Albuquerque, New Mexico, United States

NYU School of Medicine

New York, New York, United States

Eastern Carolina Women's Center

New Bern, North Carolina, United States

Wake Research Associates

Raleigh, North Carolina, United States

Hawthorne Medical Research, Inc.

Winston-Salem, North Carolina, United States

University of Cincinnati

Cincinnati, Ohio, United States

Columbus Obstetricians-Gynecology, Inc./Radiant Research, Inc.

Columbus, Ohio, United States

University of Pennsylvania School of Medicine

Philadelphia, Pennsylvania, United States

Clinical Research Of Philadelphia

Philadelphia, Pennsylvania, United States

Fellows Research Alliance, Inc.

Bluffton, South Carolina, United States

Advanced Research Associates

Corpus Christi, Texas, United States

Practice Research Organization

Dallas, Texas, United States

TMC Life Research, Inc.

Houston, Texas, United States

Physicians' Research Options

Draper, Utah, United States

Physicians' Research Options

Pleasant Grove, Utah, United States

Eastern Virginia Medical School

Norfolk, Virginia, United States

Seattle Women's Health, Research, Gynecology

Seattle, Washington, United States

Countries

United States

References

Palacios S, Colli E, Regidor PA. Efficacy and cardiovascular safety of the new estrogen-free contraceptive pill containing 4 mg drospirenone alone in a 24/4 regime. BMC Womens Health. 2020 Oct 2;20(1):218. doi: 10.1186/s12905-020-01080-9.

Reference Type: DERIVED

PMID: 33008401 (View on PubMed)

Provided Documents

Document Type: Study Protocol

View Document

Document Type: Statistical Analysis Plan

View Document

Other Identifiers

CF111/303

Identifier Type: -

Identifier Source: org_study_id